OOIR: Observatory of International Research

Papers

(The H4-Index of Europace is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
How can we assess the risk for sudden cardiac death to decide for primary prophylactic implantable cardioverter-defibrillator in patients with heart failure in 2022?	397
Atrioventricular dromotropathy: an important substrate for complete resynchronization therapy—Authors’ reply	289
Administrative data confirm safety of same-day discharge following catheter ablation of atrial fibrillation: all good or is there a fly in the ointment?	285
Anti-tachycardia pacing in ARVC: should a transvenous or subcutaneous system be used?	276
Atrial cardiomyopathy delays the endothelialization process of left atrial appendage occluders	225
Controversy: the blanking period after atrial fibrillation ablation is needed and should be maintained	205
Clinical impact of capsulectomy during cardiac implantable electronic device generator replacement: a prospective randomized trial	189
Device-lead abnormalities and function after transcatheter tricuspid valve replacement	151
Jailed or freed? The lead dilemma in transcatheter tricuspid valve replacement	149
The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study	131
Personalized subcutaneous implantable cardioverter-defibrillator sensing vectors generated by mathematical rotation increase device eligibility whilst preserving device performance	127
Mexiletine for recurrent ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter defibrillator: an EHRA systematic review	125
Impact of pulsed-field ablation on kidney function	116
Examination of pituitary adenylate cyclase-activating polypeptide (PACAP) in patients with atrial fibrillation undergoing pulmonary vein isolation	116
The effect of virtual reality on anxiety reduction in supraventricular tachycardia ablation: prospective study	103
Early detection of fluid retention with a multisensory algorithm in chronic heart failure patients	101
Benefit of integrated care in patients with atrial fibrillation- a predictive heterogeneous treatment effect analysis of the ALL-IN trial	92
Single-chamber versus dual-chamber pacing: real world data from the German national VIDEO project	92
Pulmonary vein isolation with the novel radiofrequency balloon catheter: predictors of single-shot isolation	91
Coronary sinus cannulation as real time anatomical landmark to facilitate left bundle branch area pacing	90
A leadless ventricular pacemaker providing atrioventricular synchronous pacing in the real-world setting: acute results from the Micra AV post-approval registry	89
Left bundle branch area pacing: predictors of success	86
Failed shocks in hypertrophic cardiomyopathy patients: prevalence, predictors and outcome	86
Serial arterial blood gas monitoring during deep sedation for left atrial ablation procedures: a retrospective cohort study	78
CRT with triple fusion: results of the multicentric, randomized, doble-blinded CRUSTY trial	70

Extended use of preprocedural data to detect expiratory airflow limitation in patients with atrial fibrillation scheduled for ablation	69
CIED replacement optimization: feasibility, safety and acceptability of day surgery setting for CIED replacement	64
Pulsed field ablation of the left common pulmonary vein: a new single-shot solution?	62
Analysis of mitral isthmus ablation in patients undergoing a second ablation procedure after atrial fibrillation ablation with electroporation vs. radiofrequency	60
New insights from repeated extra-cardiac vagal nerve stimulation after recent successful cardioneuroablation in high risk patients with vagally-mediated bradyarrhythmias	60
The new "olive strategy" for pulsed field ablation of atrial fibrillation: procedural data and early follow-up	59
Implementation of near zero fluoroscopy in supraventricular tachycardia ablation procedures: a single center experience	59
New onset, recurrence and progression of atrial fibrillation after cardiac surgery during 2.5 years of continuous rhythm monitoring	59
Volumetric quantification of epicardial fat using semiautomated atrial CT segmentation in patients with atrial fibrillation: the Prospective AFAT study	59
High efficacy and safety of endocardial pulsed electrical field ablation via contact force-controlled catheters for mitral isthmus ablation	58
Prevalence and clinical impact of major incidental findings detected on routine cardiovascular resonance imaging prior to catheter ablation of atrial fibrillation	57
Computed tomography as a predictive tool for ventricular tachycardia	57
Interpolation of electrophysiology parameters using OpenEP: technology development and clinical application	56
Adherence to a mobile health-based atrial fibrillation screening program: a subanalysis from STROKESTOP I and II	56
Rhythm matters: sinus and pace rhythm map significantly differ in endo/epicardial 3D electroanatomic mapping	55
Atrial endomysial fibrosis is associated with sex, atrial fibrillation, heart failure and age in cardiac surgery patients: results from the Catch-Me consortium	54
Prevalence and risk factors of pre-procedural left atrial thrombus in patients undergoing pulmonary vein isolation	54
Sudden cardiac death and atrial depolarization in coronary artery disease—Authors’ reply	52
Ablation for idiopathic ventricular arrhythmias using focal pulsed field ablation	52
Pre-diabetes increases the risk of heart failure among patients with nonvalvular atrial fibrillation	50
Preclinical evaluation of safety and efficacy of the Coherent Sine-Burst Electroporation (CSE) ablation system in a chronic porcine beating heart model	49
Management of modifiable risk factors and comorbidities in atrial fibrillation: suggestions for improvement from a patient perspective	48
Long-term effects of catheter ablation versus antiarrhythmic drugs on health-related quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial revisited	48